Lixisenatide acetate (AVE-0010; ZP-10A; Adlyxin; Lyxumia; ZP10A), the acetate salt of Lixisenatide, is a potent and short-acting agonist of the glucagon-like peptide-1 receptor (GLP-1R) approved in 2016 for the treatment of type 2 diabetes mellitus (T2DM). It activates GLP-1R with an IC50 value of 1.4 nM for the human GLP-1 receptor in in vitro receptor binding studies.

纯度：≥98%

CAS：1997361-87-1